+
  • 67482427cef2a.jpg

acellular diphtheria–tetanus–pertussis and Haemophilus influenzae type b combination vaccine


China’s first domestically developed quadrivalent vaccine; A major scientific and technological achievement under the national “863 Program.”

400 189 9806

For more product details, please contact our product experts. We look forward to your call.

Product Description

Drug name

acellular diphtheria–tetanus–pertussis–Haemophilus influenzae type b combination vaccine

Diphtheria, Tetanus, Acellular Pertussis and Haemophilus Influenzae Type B Combined Vaccine

Target population for vaccination

Infants and young children aged 3 months and older

Functions and Applications

Following vaccination with this product, a humoral immune response is elicited. It is indicated for the prevention of pertussis, diphtheria, tetanus, and invasive diseases caused by Haemophilus influenzae type b, including meningitis, pneumonia, upper respiratory tract infections, sepsis, cellulitis, arthritis, epiglottitis, and others.

Related products



undefined

undefined